So your question is about whether we can identify emerging safety signals in pharmaceuticals.
I think tremendous progress has been accomplished in the past few years in that area, especially very recently with the creation of the Canada Vigilance online database. It is a new database that will enable more efficient collection of spontaneous adverse drug reactions. It will also have a built-in data mining capacity--some kind of software that will help us identify if there are disproportional numbers of certain types of adverse events with certain drugs.